Patients with Absorb GT1 Bioresorbable Vascular Scaffold (BVS) are at greater risk of having a major cardiac event compared to patients treated with the metallic XIENCE drug-eluting stent, according to a Food and Drug Administration (FDA) Safety Communication. The BVS is used to open heart blood vessels (coronary arteries) blocked by scar tissue (plaque) in order to increase blood flow to the heart muscle. The BVS is implanted during an angioplasty procedure and gradually dissolves and is fully absorbed by the body over time. The FDA’s initial review of data from a pivitol clinical trial involving the BVS showed an ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.